Phase 3 Type 2 Diabetes Trial, Recruiting NCT06361238 Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT06361238
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 60 years of age or older
  • People who have been diagnosed with type 2 diabetes
  • People who are scheduled to have planned (non-emergency) heart surgery

Who may not be able to join:

  • People who have a history of neurological or psychiatric conditions, such as schizophrenia, epilepsy, Parkinson's disease, or severe dementia
  • People who have significant difficulties with communication, such as severe problems with vision, hearing, or speech
  • People who have a history of injury, damage, or surgery involving the brain or spinal cord
  • People whose heart condition has been assessed as the most severe category of heart failure (NYHA Class IV) (confirm with trial site)
  • People with severe liver disease, classified as Child-Pugh Class C (confirm with trial site)
  • People with severe kidney failure who require dialysis or another form of kidney replacement treatment
  • People who have a history of pancreatitis (inflammation of the pancreas)
  • People who have type 1 diabetes
  • People whose blood sugar levels cannot be kept within a specific target range during the initial screening period
  • People who have, or whose close family members have, a history of a specific type of thyroid cancer called medullary thyroid carcinoma
  • People who are pregnant or breastfeeding
  • People who have had an allergic reaction to, or cannot tolerate, a medication called liraglutide
  • People who have previously used a class of medications known as GLP-1 receptor agonists or SGLT2 inhibitors (confirm with trial site)
  • People who do not agree to sign the informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dongjin Wang, PhD,MD, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

Phone: 15751866806

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Registry
ClinicalTrials.gov
Start date
19 November 2024
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence of delirium

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov